NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
NorthSea Therapeutics appoints Morris J. Birnbaum to the Board<
21 Dec 2022

NorthSea Therapeutics appoints Morris J. Birnbaum to the Board

Former Pfizer Internal Medicine CSO joins the Board as an independent board member
Inbiomotion appoints Ralf van den Berg as Chief Operating Officer<
20 Dec 2022

Inbiomotion appoints Ralf van den Berg as Chief Operating Officer

Ralf van den Berg will drive Inbiomotion in his aim to position MAFTEST® for routine characterization of breast cancer tumors.
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa<
01 Dec 2022

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

First safety data expected in 2023 with full read-out expected in 2025
Aura Biosciences Announces Pricing of Public Offering of Common Stock<
01 Dec 2022

Aura Biosciences Announces Pricing of Public Offering of Common Stock

The offering is expected to close on or about December 5, 2022, subject to customary closing conditions.
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension<
16 Nov 2022

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

Key clinical data from Target-HTN demonstrated clinically meaningful efficacy in the treatment of patients with uncontrolled and resistant hypertension
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage<
11 Nov 2022

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage

The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft<
11 Nov 2022

Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

The aXess graft turns into a living blood vessel, promising an unprecedented, immediate and durable solution for hemodialysis patients
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe<
10 Nov 2022

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

Significant double-digit upfront payment in addition to milestone payments and development funding totaling up to EUR 258 million in the aggregate
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update<
09 Nov 2022

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients<
08 Nov 2022

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseases

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.